Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses.
Taking advantage of the ability of pentameric cholera toxin B subunit (CTB) to bind selectively to GM1, we developed recently a CTB-mediated GM1 lipid vesicle delivery system to target drugs and proteins to mucosal tissues [1]. In this report, we present the use of such a strategy to deliver an HIV envelope protein (HIV-env) to mucosal tissues via intranasal route. Intranasal administration of a recombinant HIV envelope protein formulated in CTB-associated GM1 lipid vesicles enhanced mucosal IgA antibody responses detected in the nasal and gut tissues, compared to that of control animals immunized with antigen formulated in GM1-free vesicles with CTB or formulated in alum-associated vesicles with CTB. We found a nearly 2- to 3-fold enhancement in IgA antibody titers detected both in nasal and gut tissues using the CTB-GM1 lipid vesicle delivery system, compared to using the GM1-free lipid vesicle system. Intranasal administration of HIV-env formulated in the CTB-associated GM1 vesicles also induced a significant level of serum IgG and cellular immune responses against HIV-env. IgG isotype analysis indicates that CTB in GM1 vesicle delivery system enhanced both IgG1 and IgG2a while CTB in alum formulation enhanced only IgG1. However, IgA and IgG antibody responses against CTB were similar for GM1 vesicles regardless of whether HIV-env was present in the vaccine formulation. Collectively, these data indicate that delivery of HIV-env to mucosal epithelial cells with CTB-associated GM1 lipid vesicles enhanced mucosal and systemic immune responses against the HIV-envelope protein. It is possible that both the CTB-mediated targeted delivery of antigen-loaded GM1 lipid vesicles and mucosal adjuvanticity of CTB may be involved in enhancing the immune responses.
Lian
T
T
Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, H272 Health Sciences Building, Seattle, WA 98195-7610, USA.
Bui
T
T
Ho
R J
RJ
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000378:metabolism; D002772:Cholera Toxin / Q000276:immunology* / Q000494:pharmacology; D005260:Female; D005677:G(M1) Ganglioside / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism; D005753:Gastric Mucosa / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis / Q000097:blood / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage* / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D018928:Immunity, Mucosal; D007413:Intestinal Mucosa / Q000276:immunology; D008081:Liposomes; D051379:Mice; D008810:Mice, Inbred C57BL; D009297:Nasal Mucosa / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology* / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D008081:Liposomes; D010446:Peptide Fragments; C084765:cholera toxin B subunit (50-75); D005677:G(M1) Ganglioside; D002772:Cholera Toxin